FDA clears Ensoma’s application for rare genetic disorder treatment
The FDA has cleared the IND for Ensoma's EN-374, targeting X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder.
The FDA has cleared the IND for Ensoma's EN-374, targeting X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder.
What's Your Reaction?
